Media ReleasesINOVIQ

View All INOVIQ News

INOVIQ Appendix 4C & Quarterly Activities Report - March 2022

* Collaboration with the University of Queensland (UQ) expanded to develop a worldfirst exosome-based ovarian cancer screening test
* ResearchDx, a US-based specialty contract diagnostics organisation, engaged to undertake further development and validation of SubB2M-based tests in the USA
* New funding awarded under MTPConnect’s Biomedical Translation Bridge (BTB) program to support development of INOVIQ’s SubB2M immunoassays for cancer detection
* Paper by researchers at the Institute for Glycomics, Griffith University and University of Adelaide evaluating the use of INOVIQ’s SubB2M technology in breast cancer published in BMC Cancer journal
* CSO co-authors Scientific Statement published by leading authority, The Endocrine Society, on the role of extracellular vesicles as biomarkers of disease
* Patents granted for BARD1 technology protecting BARD1 autoantibody assays for detection of breast and ovarian cancer in the USA and lung cancer in Brazil
* Cash balance of $17.3m as at 31 March 2022, representing 13 quarters of funding at current cash burn rate 

For more information, download the attached PDF.

Download this document

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.